文献速递心律失常

骨形态发生蛋白10:房颤患者缺血性卒中的新型风险标志物

Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation.
PubMed 文献 · Eur Heart J · 2023-01-01

在ACTIVE A、AVERROES和ARISTOTLE试验的房颤患者中,血浆BMP10水平与缺血性卒中风险独立相关,且不受口服抗凝治疗影响。BMP10可提高多变量模型的预测一致性指数,并与NT-proBNP独立相关。BMP10与出血或死亡无独立关联。

要点

  • BMP10与房颤患者缺血性卒中风险独立相关,无论是否抗凝。
  • BMP10可提高缺血性卒中预测模型的一致性指数。
  • BMP10与出血或死亡无独立关联。

核心结论

  • 新型心房生物标志物BMP10与房颤患者缺血性卒中独立相关,不受口服抗凝治疗影响。
  • BMP10似乎更特异地与房颤缺血性卒中风险相关。

研究设计与样本

  • 使用原型Elecsys免疫分析法分析BMP10,并通过Cox回归模型评估与结局的关联,校正临床特征、肾功能和NT-proBNP。

主要发现

  • 未抗凝和抗凝队列BMP10中位浓度分别为2.47和2.44 ng/mL。
  • BMP10升高与较低体重指数、较高年龄、女性、肾功能不全和房颤心律相关。
  • 未抗凝队列中BMP10将多变量模型一致性指数从0.713提高至0.733(P=0.004),抗凝队列从0.673提高至0.694(P<0.001)。
  • 额外校正NT-proBNP后BMP10仍保持显著预后价值。
  • BMP10与出血或死亡无独立关联。

临床怎么用

  • BMP10可能作为房颤患者缺血性卒中的新型特异性生物标志物,用于风险分层,无论是否接受口服抗凝治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Biomarkers specifically related to atrial tissue may increase the understanding of the pathophysiology of atrial fibrillation (AF) and further improve risk prediction in this setting. Bone morphogenetic protein 10 (BMP10) is a protein expressed in the atrial myocardium. We evaluated the association between BMP10 and the risk of ischaemic stroke and other cardiovascular events in large cohorts of patients with AF, treated with and without oral anticoagulation (OAC). METHODS AND RESULTS: BMP10 was measured in plasma samples collected at randomisation in patients with AF without OAC in the ACTIVE A and AVERROES trials (n = 2974), and with OAC in the ARISTOTLE trial (n = 13 079). BMP10 was analysed with a prototype Elecsys immunoassay. Associations with outcomes were evaluated by Cox-regression models adjusted for clinical characteristics, kidney function, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Median concentrations of BMP10 were 2.47 and 2.44 ng/mL, in the non-OAC and OAC cohort, respectively. Increasing BMP10 was associated with lower body mass index, older age, female sex, kidney dysfunction, and AF rhythm. BMP10 was consistently associated with ischaemic stroke. In the non-OAC cohort, BMP10 increased the concordance index of the multivariable model from 0.713 to 0.733 (P = 0.004) and in the OAC cohort from 0.673 to 0.694 (P < 0.001). Additionally, BMP10 maintained a significant prognostic value after additionally adjusting for NT-proBNP. BMP10 was not independently associated with bleeding or with death. CONCLUSION: The novel atrial biomarker BMP10 was independently associated with ischaemic stroke in patients with AF irrespective of OAC treatment. BMP10 seems to be more specifically related to the risk of ischaemic stroke in AF. ONE-SENTENCE SUMMARY: In this study, BMP10 may be a novel specific biomarker of ischaemic stroke in patients with atrial fibrillation, irrespective of oral anticoagulation.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Hijazi, Benz, Lindbäck, et al. Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation. Eur Heart J. 2023. PMID: 36380569. doi:10.1093/eurheartj/ehac632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。